Latest News for: asco

Edit

Immunofoco Presents Phase I/IIa Data of IMC002 at ASCO GI 2026, Highlighting a Durable Complete Response Beyond One Year and a 66.7% ORR in Advanced GC/GEJ

PR Newswire 13 Jan 2026
398) at the 2026 ASCO Gastrointestinal Cancers Symposium (ASCO GI 2026) ... The results presented at ASCO GI 2026 focus on the GC/GEJ cohort ... The presentation at ASCO GI 2026 highlights Immunofoco's ...
Edit

ACCENT DATA PRESENTED AT 2026 ASCO GASTROINTESTINAL CANCER SYMPOSIUM (Amplia Therapeutics Ltd)

Public Technologies 12 Jan 2026
). The text version of this document is not available ... Disclaimer ... (noodl. 128847689) .
Edit

ASCO-GI: Incyte Presentation (Incyte Corporation)

Public Technologies 12 Jan 2026
). The text version of this document is not available ... Disclaimer ... (noodl. 128853138) .
Edit

Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026 (Actuate Therapeutics Inc)

Public Technologies 12 Jan 2026
... for metastatic pancreatic cancer were featured in oral and poster presentations at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on January 9, 2026.
Edit

Alligator Bioscience to Present New OPTIMIZE-1 Data on Mitazalimab at ASCO Gastrointestinal Cancers Symposium 2026

Pharmiweb 09 Jan 2026
... untreated metastatic pancreatic ductal adenocarcinoma (mPDAC) will be presented at the ASCO Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco, CA, taking place 8-11 January 2026.
Edit

Autonomix Showcases Compelling PoC Study Clinical Data Showing Rapid and Durable Pain Relief Across All Disease Stages of Pancreatic Cancer at the 2026 ASCO Gastrointestinal (GI) Cancers Symposium (Form 8-K) (Autonomix Medical Inc)

Public Technologies 09 Jan 2026
Autonomix Showcases Compelling PoC Study Clinical Data Showing Rapid and Durable Pain Relief Across All Disease Stages of Pancreatic Cancer at the 2026 ASCO Gastrointestinal (GI) Cancers Symposium.
Edit

Phanes Therapeutics Announces Positive Phase 2 Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline (1L) Treatment of Metastatic PDAC at ASCO GI 2026

PR Newswire 09 Jan 2026
The data was presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) 2026; Abstract #709 ... Phanes' data of spevatamig featured at ASCO GI 2026 can be found here.
Edit

JAZZ ASCO GI Zani GEA Data Webcast (Jazz Pharmaceuticals plc)

Public Technologies 09 Jan 2026
). January 9, 2026 Zanidatamab. Pivotal Phase 3 HERIZON-GEA-01 Trial Results in. Gastroesophageal Adenocarcinoma (GEA). Innovating to Transform the Lives of Patients and Their Families. Intended for U.S ... Phase 3 HERIZON-GEA-01 Data Presented at ASCO GI ... II.
Edit

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium (Form 8-K) (Perspective Therapeutics Inc)

Public Technologies 09 Jan 2026
... expressing neuroendocrine tumors (NETs) are being presented as a poster presentation at the 2026 ASCO Gastrointestinal Cancers Symposium (ASCO-GI), taking place January 8-10 in San Francisco, CA.
Edit

Continued Zenocutuzumab Treatment Beyond Progression Shows Benefit in Patients with NRG1+ Pancreatic Cancer and Cholangiocarcinoma: New Results from the eNRGy Trial Presented at ASCO GI

PR Newswire 09 Jan 2026
LEXINGTON, Mass., Jan. 9, 2026 /PRNewswire/ -- Partner Therapeutics, Inc ... Results were presented in a poster session at the 2026 ASCO Gastrointestinal Cancers Symposium in San Francisco, California ... About BIZENGRI (zenocutuzumab-zbco). INDICATIONS ... 2 ... 21%.
Edit

Bexion Pharmaceuticals, Inc. Announces Poster Presentations at the American Society for Clinical Oncology (ASCO) Gastrointestinal ...

The Citizens 07 Jan 2026
COVINGTON, Ky., Jan.
Edit

SAGA Diagnostics® Presents Real-World Pathlight™ MRD Data at ASCO GI 2026

The Galveston Daily News 07 Jan 2026
MORRISVILLE, N.C.--(BUSINESS WIRE)--Jan 7, 2026-- ....
Edit

Bexion Pharmaceuticals, Inc. Announces Poster Presentations at the American Society for Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2026

PR Newswire 07 Jan 2026
7.00-7.55 AMPresenter. Michael Gazda, Ph.D.The abstracts are scheduled to be posted to the ASCO GI Online Program at 5 PM ET on Monday, January 6.
Edit

Natera Presents Updated Analyses From ALTAIR Clinical Trial at ASCO GI

The Galveston Daily News 06 Jan 2026
AUSTIN, Texas--(BUSINESS WIRE)--Jan 5, 2026-- ....
Edit

Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium

Hastings Tribune 06 Jan 2026
- Final results from first pancreatic cancer study in Montreal demonstrate 81% disease control rate, or 87% excluding the first two patients - ... .

Article Search

tools
×
×
×
×